Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$2.01 - $24.30
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$4.71M
Enterprise Value-$4.90M
Total Cash (Recent Filing)$6.91M
Total Debt (Recent Filing)$744.84K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 05, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,123,635
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-1.04
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4
Revenue Forecast (FY)$35.39M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt-to-equity reduces solvency and interest burden risk, giving management structural flexibility to fund operations or absorb regulatory delays. Over 2–6 months this lowers default risk and supports strategic choices (M&A, licensing, or continued product rollouts) without heavy fixed financing costs.
Scaled Revenue Base Vs Early YearsAn expanded revenue base provides a firmer platform to allocate fixed costs and pursue margin improvement. For a generics-focused specialty drug firm, durable revenue scale increases bargaining power with distributors and manufacturers and enhances the potential to absorb new product launches or regulatory timing variations.
Asset-light Commercial ModelRelying on third-party manufacturing and distribution keeps capital intensity low and accelerates time-to-market for new generics. Structurally, an asset-light model conserves cash and limits fixed costs, improving operational flexibility while management focuses on regulatory approvals, product acquisitions and commercialization.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow forces reliance on external capital and constrains reinvestment in commercial scale or R&D. Over months this structural cash burn raises execution risk if access to financing weakens and limits ability to sustainably fund launches or regulatory activities.
Consistent Operating LossesDespite reasonable gross margins, persistent negative EBIT/EBITDA indicates SG&A, development spend, or commercialization inefficiencies. Structurally, an inability to translate revenue scale into operating profits limits internal funding, reduces strategic optionality and keeps ROE negative across reporting periods.
Reliance On Dilutive Equity FinancingFrequent equity- and warrant-based raises (including a recent unit offering and >20% share issuance approval) signal dependence on dilution to fund operations. Over the medium term this can erode shareholder value, complicate incentive alignment and leave the company exposed if capital markets tighten.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $2.01 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $4.71M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 52 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on May 14, 2026. The company reported -$2.5 earnings per share for the quarter, the consensus estimate of -$2.5 by $0.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -1.2.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,123,635 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$2.5 in its last earnings report, expectations of -$2.5. Following the earnings report the stock price went down -28.905%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---